Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Many patients with cancer who could potentially benefit from treatment with chimeric antigen receptor (CAR)-T cells do not have access to this therapy. This Comment explores the unique barriers to a broader clinical adoption of CAR-T cell therapy and propose new routes to improve timely and equitable access to treatment.
Diverse microbial exposures in early life reduce the risk of inflammatory conditions, including allergies and autoimmunity. Emerging data suggest that microbial diversity is as important as microbial exposures for shaping the immune system. Here we highlight recent clinical trials that have attempted to restore immune regulation by increasing microbial biodiversity.
US spending in biomedicine has driven pre-eminence in academia, Nobel prizes, scientific training discovery, translation and healthcare. The associated USAID spend on global health programmes has worldwide impacts, including on the ongoing HIV eradication timeline. Current policy changes place this continued trajectory into doubt, with ramifications for international research collaborations, global health and pandemic preparedness.
Recent studies in mouse models of viral infection showed that precursors of terminally exhausted T cells emerge early during the course of disease. Here, Galluzzi discusses these findings and what they may mean for our understanding of tumour immunology and responses to immunotherapy with immune checkpoint blockade.
